Phase 3 Prostate Cancer Trial, Recruiting (NCT04794777)

Phase 3 Prostate Cancer Trial, Recruiting NCT04794777 Sponsor: Stefan Carlsson Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04794777 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have had surgery to remove your prostate (radical prostatectomy) to treat prostate cancer, and your PSA levels have risen above 0.2 but below 2.0 ng/mL on two separate measurements, suggesting the cancer may be returning.
A team of medical specialists has reviewed your case and agreed that salvage radiation therapy (radiation given after surgery) is an appropriate treatment option for you.
You are willing and able to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

You have previously been treated for prostate cancer and have already experienced a biochemical recurrence (a rise in PSA after treatment) (confirm with trial site, as this may overlap with the inclusion criteria).
You have received hormone therapy (medication to reduce testosterone levels) at any point after your prostate surgery.
You have previously had radiation therapy to the pelvic area.
During your prostate surgery, cancer was found to have spread to your lymph nodes.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Stefan Carlsson, Karolinska University Hospital

Phone: 0704871106

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04794777

Sponsor: Stefan Carlsson

Phase: Phase 3

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 0704871106

More information: https://clinicaltrials.gov/study/NCT04794777

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have had surgery to remove your prostate (radical prostatectomy) to treat prostate cancer, and your PSA levels have risen above 0.2 but below 2.0 ng/mL on two separate measurements, suggesting the cancer may be returning.
A team of medical specialists has reviewed your case and agreed that salvage radiation therapy (radiation given after surgery) is an appropriate treatment option for you.
You are willing and able to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

You have previously been treated for prostate cancer and have already experienced a biochemical recurrence (a rise in PSA after treatment) (confirm with trial site, as this may overlap with the inclusion criteria).
You have received hormone therapy (medication to reduce testosterone levels) at any point after your prostate surgery.
You have previously had radiation therapy to the pelvic area.
During your prostate surgery, cancer was found to have spread to your lymph nodes.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Stefan Carlsson

Registry

ClinicalTrials.gov

Start date

30 October 2018

Est. completion

30 October 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Primary PSA progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov